A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...
A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...
Intellia Therapeutics, Inc. is rated Hold due to uncertainty from dosing pause in its MAGNITUDE program for ATTR. Learn more ...
Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...
Research from UChicago dissects how a single genetic switch helps butterflies mimic wing patterns of other species to protect ...
Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...
Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...
Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses. CRISPR/Cas systems, originally derived from bacterial immune responses, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback